Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue

• US 8,326,416 B2
• Filed: 10/25/2010
• Issued: 12/04/2012
• Est. Priority Date: 03/10/2003
• Status: Active Grant

• Current Assignee: Impulse Dynamics NV
• Original Assignee: Impulse Dynamics NV
• Inventors: Mika, Yuval, Sabbah, Hani N., Haddad, Walid, Rousso, Benny
• Primary Examiner(s): Layno, Carl H.
• Assistant Examiner(s): MORALES, JON ERIC C
• Application Number:
  US12/910,943
• Publication Number:
  US 20110093028A1
• Time in Patent Office: 771 Days
• Field of Search: 607/3, 607/4
• US Class Current: 607/2
• CPC Class Codes: A61N 1/0587 Epicardial electrode systems; Endocardial electrodes piercing the pericardium
• CPC Class Codes: A61N 1/326 for promoting growth of cells, e.g. bone cells
• CPC Class Codes: A61N 1/3627 for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy
• CPC Class Codes: A61N 1/36557 controlled by chemical substances in blood
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

Method and apparatus for modifying gene expression in cardiac muscle cells, by the application of electric fields. In some embodiments, the modification provides treatment of heart failure. Optionally, the treatment also provides an immediate improvement in cardiac function.

Claims

1. A method of normalizing the expression levels of a plurality of cardiac genes comprising determining that a patient has a cardiac disease associated with abnormal gene expression in a plurality of cardiac genes;

and applying an electric field to diseased cardiac cells in an in-vivo heart using suitable parameters and for a sufficient duration to have said normalization effect on the expression levels of said plurality of cardiac genes in said diseased cardiac cells.

2. A method according to claim 1, wherein said electric field includes a non-excitatory portion.

3. A method according to claim 1, wherein said electric field includes an excitatory portion.

4. A method according to claim 1, wherein said duration is between 1 and 12 hours.

5. A method according to claim 1, wherein said duration includes four hours of application.

6. A method according to claim 1, wherein said applying does not have a substantial acute effect on cardiac output.

7. A method according to claim 1, wherein said applying also has an immediate beneficial effect on cardiac function.

8. A method according to claim 1, wherein said normalization comprises normalization to within 30% of baseline levels.

9. A method according to claim 1, wherein said applying comprises intermittent application.

10. A method according to claim 1, wherein said electric field includes a portion including a train of between 1 and 5 biphaisc pulses applied within a single beat, with a delay from local activation of less than 100 milliseconds.

11. A method according to claim 1, wherein normalization includes increasing a secretion into a blood stream by at least 50%, of a material.

12. A method according to claim 1, comprising estimating an effect of said electric field on said gene expression and modifying said applying in response to said estimating.

13. A method according to claim 1, wherein applying comprises applying not every beat and also including a break in said applying.

14. A method according to claim 1, wherein applying comprises not applying during an arrhythmia.

15. A method according to claim 1, wherein applying comprises applying to a heart using an implantable device.

16. A method according to claim 1, wherein said normalization in expression lasts after said signal is stopped.

17. A method according to claim 1, wherein said normalization in expression lasts at least one week after said signal is stopped.

18. A method according to claim 1, wherein said normalization comprises a reversal in progression of heart failure.

19. A method according to claim 1, wherein said modification in expression is associated with an improvement in cardiac function.

20. A method according to claim 19, wherein said improvement in cardiac function comprises an improvement in contractility.

21. A method according to claim 19, wherein said improvement in cardiac function comprises a reduction in arrhythmia.

22. A method according to claim 1, wherein said applying comprises applying after identifying a protocol of applying which is expected to provide a modification in accordance with said normalization.

23. A method according to claim 1, comprising repeating said applying to maintain said normalization.

24. A method according to claim 1, comprising repeating said applying to achieve said normalization.

25. A method according to claim 1, wherein said expression comprises mRNA levels.

26. A method according to claim 1, wherein said normalizations comprises at least one up-regulation and at least one down-regulation.

27. A method according to claim 1, wherein said genes include at least one gene from a group consisting of BNP, ANP, bFGF, aMHC and connexin 43.

28. A method according to claim 1, wherein applying comprises applying to a ventricle of said heart.

29. A method according to claim 1, wherein determining comprises determining that the expression levels of said plurality of cardiac genes is abnormal.

30. A method according to claim 1, wherein determining comprises determining using plasma levels of one or more peptides.

31. A method according to claim 1, wherein determining comprises determining using gene expression level assessment.

32. A method according to claim 1, wherein said normalizing is evidenced by plasma levels of one or more peptides.

33. A method according to claim 1, wherein said normalizing is evidenced by gene expression levels in cardiac tissue.

34. A method according to claim 1, comprising monitoring the normalization of gene expression levels.

35. A method according to claim 1, wherein said normalizing comprises restoring to above normal levels of at least one gene expression level.

36. A method according to claim 1, wherein said normalization comprises a reversal of a fetal gene program.

37. A method according to claim 1, wherein said normalizing comprises reducing an expression level of at least one gene by at least 50%.

38. A method according to claim 1, comprising deducing a gene expression level from one or both of a mechanical sensor and an electrical sensor.

39. A method according to claim 1, wherein said electric field includes a portion including a train of between 1 and 5 biphaisc pulses applied within a single beat.

40. A method according to claim 1, wherein said electric field is applied at a delay from local activation of less than 100 milliseconds.

41. A method of programming a cardiac stimulator, comprising:

(a) determining a desired normalization effect of said stimulator on at least two cardiac genes for treating a cardiac disease associated with abnormal gene expression in a plurality of cardiac genes; and

(b) programming said stimulator with signal application parameters suitable for providing said normalization effect on the expression levels of said at least two cardiac genes in said diseased cardiac cells.

42. A method according to claim 41, wherein said signal parameters include parameters for a non-excitatory electric field portion.

43. A method according to claim 41, wherein said signal parameters include a duration of application of between 1 and 12 hours.

44. A method according to claim 41, wherein said signal parameters include electric field parameters including a train of between 1 and 5 biphaisc pulses applied within a single beat, with a delay from local activation of less than 100 milliseconds.

45. A method according to claim 41, wherein said signal parameters comprise parameters for applying not every beat and also including a break in said applying.

46. A method according to claim 41, wherein said programming comprises programming a response of said stimulator to a signal from one or both of a mechanical sensor and an electrical sensor.

47. A method of normalizing the expression levels of a plurality of cardiac genes comprising applying an electric field to in an in-vivo heart using suitable parameters and for a sufficient duration to have said normalization effect, wherein said normalization comprises normalization to within 30% of baseline levels.